Seretide 125 Evohaler - Summary of Product Characteristics
Seretide Evohaler should not be used to treat acute asthma symptoms for which a fast and short-acting bronchodilator is required. Patients should be advised to have their inhaler to be used for relief in an acute asthma attack available at all times.
SERETIDE. 適用於嚴重慢性阻塞性肺部疾病(FEV. 1 <50%預期值，FEV. 1 /FVC<70％) 之維持治療，包括慢性支氣管炎和肺氣腫。 【劑量與用法】 本藥須由醫師處方使用。 SERETIDE . Evohaler. 僅供吸入使用。 病人必須明白，即使沒有症狀，仍須常規使用. SERETIDE. Evohaler ， …
SERETIDE 125 EVOHALER - patient leaflet, side effects, dosage
Fluticasone propionate is a corticosteroid which reduces swelling and irritation in the lungs. The doctor has prescribed this medicine to help prevent breathing problems such as asthma. You must use Seretide every day as directed by your doctor. This will make sure that it works properly in controlling your asthma.
Each single actuation of SERETIDE provides: Salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 50, 125 or 250 micrograms of fluticasone propionate. CLINICAL INFORMATION Indications Pharmaceutical form: Inhalation aerosol. ASTHMA (Reversible Obstructive Airways Disease) SERETIDE is indicated in the regular treatment of asthma ...
- [PDF]
SERETIDE - Medsafe
different strengths of SERETIDE MDI for you, depending on the severity of your condition: • SERETIDE MDI 50/25 (50 micrograms of fluticasone propionate and 25 micrograms of salmeterol), or • SERETIDE MDI 125/25 (125 micrograms of fluticasone propionate and 25 micrograms of salmeterol), or SERETIDE MDI 250/25 (250 micrograms of fluticasone
Seretide Evohaler 125,250 使肺泰優氟 125,250 - GSK
產品英文名稱：Seretide Evohaler 125,250; 產品主成分：Salmeterol, Fluticasone Propionate Seretide Evohaler 125,250 使肺泰優氟125,250 完整仿單下載PDF - 988KB. Seretide, Evohaler, 使肺泰及優氟為葛蘭素史克集團所有或經授權的商標
BC23481157 | 藥品資訊 | 就醫指南 | 天主教耕莘醫療財團法人耕莘 …
SERETIDE適用於可逆性呼吸道阻塞疾病 (ROAD)之常規治療，包括適合使用支氣管擴張劑及皮質類固醇組合療法之患有氣喘的兒童與成人。 這可能包括：正在使用長效乙型作用劑 (β-AGONIST)及吸入型皮質類固醇之有效維持劑量的患者。 正在接受吸入型皮質類固醇療法，而仍有症狀之患者。 接受支氣管擴張劑之常規治療，而需要吸入型皮質類固醇之患者。 SERETIDE適用於嚴重慢性阻塞性肺部疾病 (FEV1 <50%預期值，FEV1/FVC<70%)之維持治療，包括慢性支 …
Seretide 125 Evohaler 25 microgram/125 microgram/dose
The objective of the Health Products Regulatory Authority is to ensure in so far as possible, consistent with current medical and scientific knowledge, the quality, safety and efficacy of medicines available in Ireland and to participate in systems designed to do that throughout the European Union.
Seretide MDI 125/25 - healthdirect
For the symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. Seretide is not indicated for the initiation of bronchodilator therapy in COPD. This medicine contains one component only.
使肺泰125優氟吸入劑 SERETIDE 125 EVOHALER @ 藥要看
SERETIDE適用於嚴重慢性阻塞性肺部疾病 (FEV1<50%預期值，FEV1/FVC<70%)之維持治療，包括慢性支氣管炎和肺氣腫。 使肺泰125優氟吸入劑 SERETIDE 125 EVOHALER 的適應症為 SERETIDE適用於可逆性呼吸道阻塞疾病 (ROAD)之常規治療，包括適合使用支氣管擴張劑及皮質類固醇組合療法之患有氣喘的兒童與成人。 這可能包括：正在使用長效乙型作用劑 (β-AGONIST)及吸入型皮質類固醇之有效維持劑量的患者。 正在接受吸入型皮質類固醇療法，而 …